Rituximab
- PDF / 169,318 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 58 Downloads / 153 Views
1 S
Rituximab Urinary tract infection caused by Escherichia coli and fatal respiratory infection: 2 case reports
In a retrospective, multicentric, observational study of 20 patients with chronic forms of hypersensitivity pneumonitis, who had been treated with rituximab between 8 January 2014 and 14 June 2019, two patients were described [ages and sexes not stated], who developed urinary tract infection with Escherichia coli or fatal respiratory infection following administration of rituximab for chronic hypersensitivity pneumonitis. The two patients, who had a history of chronic hypersensitivity pneumonitis received infusions of rituximab injections [dosage and route not stated]. They were also receiving prednisone. Within 12 months of the first injection of rituximab they developed rituximab attributed infections; one patient developed an urinary tract infection caused by Escherichia coli [outcome not stated] and the other patient developed respiratory infection. The patient, who developed respiratory infection died due to the infection. Ferreira M, et al. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. Respiratory 803517813 Medicine 172: 106146, Oct 2020. Available from: URL: http://doi.org/10.1016/j.rmed.2020.106146
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
